Milk-based therapies could be coming. This biotech CEO is aiming to lead the way.

Intrinsic Medicine is entering phase 2 trials in Parkinson’s disease and IBS for its human milk oligosaccharide drug candidates next year.

By Amy Baxter • Dec. 2, 2024

Specialized CROs aim to boost participation among women and other underrepresented groups

Lindus Health’s women-focused CRO is the latest in a handful of research efforts to target specialized — and underrepresented — populations.

By Alexandra Pecci • Nov. 27, 2024

Explore the Trendline➔

Artificial intelligence & machine learning

After years of excited buzz around the potential of artificial intelligence and machine learning, pharma has begun to realize the true implications and potential value of these technologies.

By PharmaVoice staff

An RNA biotech draws the blueprint for a late-stage Dravet syndrome trial and beyond

Stoke Therapeutics is entering phase 3 with its RNA medicine designed to treat a rare epileptic condition.

By Michael Gibney • Nov. 26, 2024

Trump nominees want to slash and burn agencies. Will RFK Jr. and Oz do the same in healthcare?

Both Trump appointees have promised to bring sweeping changes to several healthcare agencies. 

By Amy Baxter • Nov. 25, 2024

Will Walgreens’ store closures derail its clinical trial aims?

Despite a plan to shutter 1,200 stores, the company’s chief clinical trials officer said the pharmacy juggernaut remains committed to drug research.

By Meagan Parrish • Nov. 22, 2024

Pfizer, under pressure to change, names oncology head as new R&D chief

Chris Boshoff will replace Mikael Dolsten, who’s stepping down after 15 years leading research at the drugmaker.

By Kristin Jensen • Nov. 21, 2024

Keytruda represents almost half of Merck’s sales, and a new formulation could fend off rivals

A subcutaneous version of Merck’s Keytruda was as effective as the infused version in a late-stage study, but the company won’t be the first to market.

By Michael Gibney • Nov. 21, 2024

What is a ‘cure,’ really? AbbVie’s Humira creator leaps into the next phase of medicine

AbbVie’s head of R&D cures has lofty ambitions to end diseases like HIV through a community of researchers that work as one.

By Michael Gibney • Nov. 19, 2024

The Dodgers’ World Series run brought attention to a rare disease. Annexon is stepping up to the plate.

The company is looking to score an FDA nod for its investigational therapy that targets a molecule linked to Guillain-Barré syndrome and other autoimmune diseases.

By Alexandra Pecci • Nov. 19, 2024

Why Merck rolled the dice on an ‘unbelievable’ early-stage brain cancer drug

Merck’s acquisition of Modifi Biosciences bucks common M&A trends in pharma. 

By Kelly Bilodeau • Nov. 18, 2024

The first MASH drug could open the door for others — including GLP-1s

With only one approved drug on the market, companies like Inventiva Pharma are advancing MASH drugs and seeking a competitive edge.

By Amy Baxter • Nov. 18, 2024

Where are they now? 4 biotechs that soared then crashed during the pandemic

How Novavax and others have restructured and trudged forward after their COVID-era high.

By Meagan Parrish • Nov. 15, 2024

Pharma’s grip on cancer R&D is having unintended consequences

A pair of studies paint a complicated picture of funding and missed research opportunities.

By Alexandra Pecci • Nov. 12, 2024

Spravato is just the beginning in a new wave of depression meds

Psychiatry is getting more targeted as drugmakers develop a new range of treatments for depression.

By Meagan Parrish • Nov. 11, 2024

An RNAi renaissance is creating a new generation of startups

Pioneers like Alnylam Pharmaceuticals have led the RNA interference field for years. Now, a crop of young biotechs is building on that foundation by taking the drugmaking technology in new directions.

By Gwendolyn Wu • Nov. 7, 2024

A diabetes drug, twice rejected, stumbles again — but its developer persists

After multiple rejections, Lexicon Pharmaceuticals is inching toward an FDA decision date next month for its adjunct type 1 diabetes therapy.   

By Amy Baxter • Nov. 6, 2024

Two former Alexion leaders fight through a tough market to maintain a rare disease biotech

Rallybio is headed into a mid-stage trial with enough cash through 2026, but the cyclical market has made the journey difficult.

By Michael Gibney • Nov. 5, 2024

CEO with type 1 diabetes works to deliver ‘world’s first’ functional cure

Sernova’s technology helped type 1 diabetes patients achieve insulin independence in early- and mid-stage trials.

By Alexandra Pecci • Nov. 5, 2024

Pharma takes aim at a wily foe — the Epstein-Barr virus

The pernicious and widespread virus has been linked to a range of diseases including MS and long COVID.

By Kelly Bilodeau • Nov. 4, 2024

Pfizer’s quest for market share in the ‘high stakes battleground’ of oral GLP-1s

Pfizer’s second-to-market goals for its oral GLP-1 drugs underscore big opportunities in the space.

By Amy Baxter • Nov. 4, 2024

A sickle cell cure exists. But patients need more than just gene therapy.

Almost a year after two historic approvals, Pfizer is pulling a sickle cell disease treatment from the market, and the outlook for patients feels shakier.

By Alexandra Pecci • Nov. 1, 2024

2024 PharmaVoice 100s: Cancer Care Visionaries

Leaders who envision a world without cancer through oncology innovation.

By Michael Gibney • Nov. 1, 2024

2024 PharmaVoice 100s: Clinical Trial Pros

Experts raising the bar in clinical trial design and collaboration.

By Amy Baxter • Oct. 31, 2024

Big Pharma earnings hang hope on the next generation of blockbusters

Pfizer, J&J, Biogen and Novartis are banking on new products to make up for maturing blockbusters, but future growth is not guaranteed.

By Michael Gibney • Oct. 31, 2024

2024 PharmaVoice 100s: Cell and Gene Therapy Pioneers

Leaders molding the cutting-edge cell and gene therapy field into tomorrow's cures.

By Michael Gibney • Oct. 30, 2024